Paper Details

  1. Home
  2. Paper Details

Adverse events of radioimmunotherapy for non-Hodgkin lymphoma: A systematic review and meta-analysis.

Author: DaliaSamir, GruhonjicHanan, HannaCatherine H, Juárez-SalcedoLuis Miguel, MhaskarRahul, PatelRaahil S, PonnagantiBharat S, ShardaEsha

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This meta-analysis evaluated the association between radioimmunotherapy (RIT) and the development of second neoplasms, specifically acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), in patients with non-Hodgkin's lymphoma (NHL). While RIT shows promise in treating NHL, this study aimed to determine the safety of the therapy by assessing the incidence of these secondary cancers.
Paper Details　
Original Abstract of the Article :
Non-Hodgkin's lymphoma continues to be a highly prevalent entity in the general population. Currently, there are multiple treatment schemes based on chemotherapeutic agents with a great success rate. However, there is a non-negligible percentage of patients who may relapse or be refractory. In this ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.leukres.2021.106615

データ提供：米国国立医学図書館（NLM）

Radioimmunotherapy for Non-Hodgkin Lymphoma: Balancing Benefits and Risks

This research delves into the realm of cancer treatment, a field as complex and challenging as navigating a vast desert. The study focuses on radioimmunotherapy (RIT), a treatment approach for non-Hodgkin lymphoma, and investigates the potential risks and benefits of this therapy. This research is crucial for understanding the potential side effects of RIT, ensuring informed decision-making in cancer care.

Radioimmunotherapy: A Powerful Weapon Against Lymphoma

The researchers found that RIT is a promising treatment option for non-Hodgkin lymphoma, but it can be associated with the risk of second neoplasms, such as acute myeloid leukemia. This study emphasizes the importance of weighing the potential benefits against the potential risks of RIT.

Navigating Cancer Treatment

This research provides valuable insights into the complex landscape of cancer treatment, highlighting the importance of informed decision-making and careful risk-benefit assessment when considering RIT as a therapeutic option.

Dr.Camel's Conclusion

This research reminds us that the journey of cancer treatment is a balancing act. Just as a desert traveler must carefully weigh the risks and rewards of their path, healthcare professionals and patients must carefully consider the potential benefits and risks of different treatments. This study sheds light on the complexities of radioimmunotherapy, offering valuable information to guide informed decision-making in cancer care.

Date :
  1. Date Completed 2021-09-21
  2. Date Revised 2023-09-06
Further Info :

Pubmed ID

34052662

DOI: Digital Object Identifier

10.1016/j.leukres.2021.106615

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.